Genmab: Late-Stage Oncology Pipeline Catalysts Underpin Buy Rating and Upside Potential

In a report released today, Charlie Haywood from Bank of America Securities maintained a Buy rating on Genmab A/S, with a price target of DKK2,250.00.

Charlie Haywood has given his Buy rating due to a combination of factors tied to Genmab’s late-stage pipeline and competitive positioning. He sees substantial upside from three key 2026 catalysts, particularly the Phase III programs for petosemtamab in head and neck cancer, where early data suggest a materially higher response rate and survival potential versus current Keytruda-based standards of care, with a viable chemo‑free regimen and meaningful timing and dosing advantages over emerging rivals. Genmab’s detailed review of patient-level data and manageable safety profile further strengthen confidence in this asset, including additional opportunities in colorectal cancer and locally advanced head and neck disease.
Haywood also highlights the value of Rina-S in platinum-resistant ovarian cancer and endometrial cancer, where it demonstrates broad activity across FRα expression levels, strong durability of response, and a cleaner safety profile versus Elahere and other FRα competitors, supported by a convenient dosing schedule and an emerging combination strategy. Finally, he remains constructive on Epkinly in first-line DLBCL, expecting Phase II data that could compare favorably with existing regimens and peers, supported by prior strong hazard ratios and a more convenient subcutaneous administration profile. Together with Genmab’s solid balance sheet and the proximity of these pivotal readouts and potential filings, these dynamics justify maintaining a Buy rating and a price objective above the current share price.